Correlation of MDR1 expression and oncogenic activation in human epithelial ovarian carcinoma

Anticancer Research

Volumn 17, Issue 3 C, 1997, Pages 2147-2151

  Schneider, J ^a,c   Centeno, Mar ^a   Jimenez, Elisa ^a   Rodriguez Escudero, F J ^a   Romero, H ^a,b  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b UNIVERSIDAD DEL CAUCA   (Colombia)

^c HOSPITAL DE CRUCES   (Spain)

Author keywords

c erb B2; MDR; nm23; Ovarian cancer; p53

Indexed keywords

GLYCOPROTEIN P; PROTEIN P53;

ARTICLE; CANCER STAGING; CLINICAL ARTICLE; FEMALE; GENE ACTIVATION; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MULTIDRUG RESISTANCE; ONCOGENE; ONCOGENE C ERB; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE;

ANTIGENS, NEOPLASM; BREAST NEOPLASMS; DRUG RESISTANCE, MULTIPLE; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; MONOMERIC GTP-BINDING PROTEINS; NEOPLASM STAGING; NUCLEOSIDE-DIPHOSPHATE KINASE; OVARIAN NEOPLASMS; P-GLYCOPROTEIN; RECEPTOR, ERBB-2; TRANSCRIPTION FACTORS;

EID: 0030843263     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Deuchars KL and Ling V: P-glycoprotein and multirug resistance in cancer chemotherapy. Semin Oncol 16: 156-165, 1989.
2. van Kalken CK, Pinedo HM and Giaccone G: Multidrug resistance from the clinical point of view. Eur J Cancer 11: 1481-1486, 1991.
3. Bradley G, Sharma R, Rajalakshmi S and Ling V: P-glycoprotein expression during tumor progression in the rat liver. Cancer Res 52: 5154-5161, 1992.
4. Chin KW, Ueda K, Pastan I and Gottesman MM: Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science 255: 459-462, 1992.
5. Schneider J, Rubio MP, Barbazan MJ, Rodriguez-Escudero FJ, Seizinger BR and Castresana JS: P-glycoprotein, HER-2/neu, and mutant p53 expression in human gynecologic tumors. J Natl Cancer Inst 86: 850-855, 1994.
6. Schneider J and Romero H: Correlation of P-glycoprotein overexpression and cellular prognostic factors in formalin-fixed, paraffin-embedded tumor samples from breast cancer patients. Anticancer Res 15: 1117-1122, 1995.
7. Meden H, Marx D, Rath W, Kron M, Fattahi-Meibodi A, Hinney B, Kuhn W and Schauer A: Overexpression of the oncogene c-erb-B2 in primary ovarian cancer: evaluation of the prognostic value in a Cox proportional hazards multiple regression. Int J Gynecol Pathol 13: 45-53, 1994
8. Schneider J, Romero H, Ruiz R, Centeno MM and Rodriguez-Escudero FJ: nm23 expression in advanced and borderline ovarian carcinoma. Anticancer Res 16: 1197-1202, 1996
9. Kellen JA. Molecular interrelationships in multidrug resistance. Anticancer Res 14: 433-436, 1994
10. Burt RK, Garfield S, Johnson K and Thorgeirsson SS: Transformation of rat liver epithelial cells with v-H-Ras or v-raf causes expression of MDR-1, glutathione-S-transferase-P and increased resistance to cytotoxic chemicals. Carcinogenesis 9: 2329-2332, 1988.
11. Sklar MD: Increased resistance to cis-diaminodichloro-platinum (II) in NIH 3T3 cells transformed by ras oncogenes. Cancer Res 48: 793-807, 1988.
12. Sklar MD: The ras oncogenes increase the intrinsic resistance of NIH 3T3 cells to ionizing radiation. Science 289: 645-647, 1988.
13. Kadoyama C, Birrer M, Dosaka H, Lai S, Venzon D and Gazdar A: Transfection with H-ras or c-myc proto-oncogenes results in induction of multidrug resistant phenotype. Proc Amer Assoc Cancer Res 30: 501, 1989.
14. Weinstein RS, Jakate SM, Dominguez JM, Lebowitz MD, Koukoulis GK, Kuszak JR, Klusens LF, Grogan TM, Saclarides TJ and Roninson IB: Relationship of the expression of the multidrug resistance gene product (P-glycoprotein) in human colon carcinoma to local tumor aggressiveness and lymph node metastasis. Cancer Res 51: 2720-2726, 1991.
15. Volm M: P-glycoprotein associated expression of c-fos and c-jun products in human lung carcinomas. Anticancer Res 13: 375-378, 1993.